

# Jeremy S Setton

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2520741/publications.pdf>

Version: 2024-02-01

24  
papers

1,198  
citations

471509

17  
h-index

677142

22  
g-index

24  
all docs

24  
docs citations

24  
times ranked

2531  
citing authors

#	ARTICLE	IF	CITATIONS
1	Intensity-Modulated Radiotherapy in the Treatment of Oropharyngeal Cancer: An Update of the Memorial Sloan-Kettering Cancer Center Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 291-298.	0.8	168
2	The therapeutic significance of mutational signatures from DNA repair deficiency in cancer. <i>Nature Communications</i> , 2018, 9, 3292.	12.8	153
3	Distinct Classes of Complex Structural Variation Uncovered across Thousands of Cancer Genome Graphs. <i>Cell</i> , 2020, 183, 197-210.e32.	28.9	141
4	Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. <i>Nature Cancer</i> , 2020, 1, 1188-1203.	13.2	114
5	A multi-institution pooled analysis of gastrostomy tube dependence in patients with oropharyngeal cancer treated with definitive intensity-modulated radiotherapy. <i>Cancer</i> , 2015, 121, 294-301.	4.1	109
6	Synthetic Lethality in Cancer Therapeutics: The Next Generation. <i>Cancer Discovery</i> , 2021, 11, 1626-1635.	9.4	91
7	Efficacy of concurrent cetuximab vs. 5-fluorouracil/carboplatin or high-dose cisplatin with intensity-modulated radiation therapy (IMRT) for locally-advanced head and neck cancer (LAHNSCC). <i>Oral Oncology</i> , 2014, 50, 947-955.	1.5	51
8	Long-term patterns of relapse and survival following definitive intensity-modulated radiotherapy for non-endemic nasopharyngeal carcinoma. <i>Oral Oncology</i> , 2016, 53, 67-73.	1.5	44
9	Definitive treatment of metastatic nasopharyngeal carcinoma: Report of 5 cases with review of literature. <i>Head and Neck</i> , 2012, 34, 753-757.	2.0	41
10	Estimate of the impact of FDG-avidity on the dose required for head and neck radiotherapy local control. <i>Radiotherapy and Oncology</i> , 2014, 111, 340-347.	0.6	38
11	Pathogenic <i>ATM</i> Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 266-273.	6.3	38
12	Dose-volume factors correlating with trismus following chemoradiation for head and neck cancer. <i>Acta Oncologica</i> , 2016, 55, 99-104.	1.8	36
13	The relative prognostic utility of standardized uptake value, gross tumor volume, and metabolic tumor volume in oropharyngeal cancer patients treated with platinum based concurrent chemoradiation with a pre-treatment [18F] fluorodeoxyglucose positron emission tomography scan. <i>Oral Oncology</i> , 2014, 50, 802-808.	1.5	34
14	Genomic analysis of exceptional responders to radiotherapy reveals somatic mutations in <i>ATM</i> . <i>Oncotarget</i> , 2017, 8, 10312-10323.	1.8	31
15	Radiation field design and regional control in sentinel lymph node-positive breast cancer patients with omission of axillary dissection. <i>Cancer</i> , 2012, 118, 1994-2003.	4.1	25
16	Patients with low lying lymph nodes are at high risk for distant metastasis in oropharyngeal cancer. <i>Oral Oncology</i> , 2014, 50, 863-868.	1.5	20
17	The Landscape of Somatic Genetic Alterations in Breast Cancers from CHEK2 Germline Mutation Carriers. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz027.	2.9	20
18	Patterns of nodal failure after intensity modulated radiotherapy for nasopharyngeal carcinoma. <i>Laryngoscope</i> , 2017, 127, 377-382.	2.0	16

#	ARTICLE	IF	CITATIONS
19	Homologous recombination deficiency: how genomic signatures are generated. <i>Current Opinion in Genetics and Development</i> , 2021, 66, 93-100.	3.3	13
20	Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination. <i>Npj Breast Cancer</i> , 2021, 7, 135.	5.2	9
21	Moving beyond PARP Inhibition in ATM-Deficient Prostate Cancer. <i>Cancer Research</i> , 2020, 80, 2085-2086.	0.9	3
22	<i>ATM</i> Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications. <i>Journal of the National Cancer Institute</i> , 2022, 114, 761-770.	6.3	3
23	A new role for a tumor-suppressing protein. <i>ELife</i> , 2018, 7, .	6.0	0
24	Melanoma metastatic to multiple visceral organs: further considerations. <i>Oncology</i> , 2010, 24, 654-5.	0.5	0